Antibiotic Resistance of Helicobacter pylori in Eastern China: An Updated Multicenter Cross-Sectional Surveillance Study From 2022 to 2025

IF 4.6 2区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Helicobacter Pub Date : 2026-10-21 DOI:10.1111/hel.70170

Shihan Xu, Yifan Qiu, Jiayue Wang, Chanjuan Wang, Xianzhu Zhou, Huiyun Zhu, Wenbo Zhu, Pei Xie, Liting Shen, Huabing Huang, Xintong Zhao, Hengjun Gao, Zhaoshen Li, Yiqi Du

{"title":"Antibiotic Resistance of Helicobacter pylori in Eastern China: An Updated Multicenter Cross-Sectional Surveillance Study From 2022 to 2025","authors":"Shihan Xu, Yifan Qiu, Jiayue Wang, Chanjuan Wang, Xianzhu Zhou, Huiyun Zhu, Wenbo Zhu, Pei Xie, Liting Shen, Huabing Huang, Xintong Zhao, Hengjun Gao, Zhaoshen Li, Yiqi Du","doi":"10.1111/hel.70170","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Rising <i>Helicobacter pylori</i> antibiotic resistance compromises efficacy of empirical eradication therapies. This study aimed to provide updated, region-specific resistance data in Eastern China to guide empirical treatment strategies.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>A multicenter, cross-sectional study was conducted across 30 institutions in Eastern China from 2022 to 2025. Susceptibility to six antibiotics was evaluated using the Kirby-Bauer disk diffusion method.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>A total of 1088 <i>H. pylori</i> isolates from gastric biopsies were analyzed. Resistance rates were exceptionally high for metronidazole (93.8%), clarithromycin (71.0%), and levofloxacin (61.2%), whereas resistance to amoxicillin, furazolidone, and tetracycline remained universally low (< 1%). Multidrug resistance (MDR) was highly prevalent at 80.0%. However, resistance to metronidazole, levofloxacin, and clarithromycin showed decreasing trends over the study period.</p>\n </section>\n \n <section>\n \n <h3> Interpretation</h3>\n \n <p>Given the alarming resistance levels, empirical use of clarithromycin- and levofloxacin-based regimens should be approached with caution in Eastern China. Where universal susceptibility testing is not accessible, there is an urgent need to explore and validate novel, effective empirical eradication regimens and to establish sustained regional resistance surveillance networks to dynamically refine <i>H. pylori</i> management strategies.</p>\n </section>\n </div>","PeriodicalId":13223,"journal":{"name":"Helicobacter","volume":"31 5","pages":""},"PeriodicalIF":4.6000,"publicationDate":"2026-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Helicobacter","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/hel.70170","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Rising Helicobacter pylori antibiotic resistance compromises efficacy of empirical eradication therapies. This study aimed to provide updated, region-specific resistance data in Eastern China to guide empirical treatment strategies.

Methods

A multicenter, cross-sectional study was conducted across 30 institutions in Eastern China from 2022 to 2025. Susceptibility to six antibiotics was evaluated using the Kirby-Bauer disk diffusion method.

Results

A total of 1088 H. pylori isolates from gastric biopsies were analyzed. Resistance rates were exceptionally high for metronidazole (93.8%), clarithromycin (71.0%), and levofloxacin (61.2%), whereas resistance to amoxicillin, furazolidone, and tetracycline remained universally low (< 1%). Multidrug resistance (MDR) was highly prevalent at 80.0%. However, resistance to metronidazole, levofloxacin, and clarithromycin showed decreasing trends over the study period.

Interpretation

Given the alarming resistance levels, empirical use of clarithromycin- and levofloxacin-based regimens should be approached with caution in Eastern China. Where universal susceptibility testing is not accessible, there is an urgent need to explore and validate novel, effective empirical eradication regimens and to establish sustained regional resistance surveillance networks to dynamically refine H. pylori management strategies.

查看原文本刊更多论文

中国东部幽门螺杆菌抗生素耐药性：2022 - 2025年最新多中心横断面监测研究

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Helicobacter 医学-微生物学

CiteScore

8.40

自引率

9.10%

发文量

审稿时长

2 months

期刊介绍： Helicobacter is edited by Professor David Y Graham. The editorial and peer review process is an independent process. Whenever there is a conflict of interest, the editor and editorial board will declare their interests and affiliations. Helicobacter recognises the critical role that has been established for Helicobacter pylori in peptic ulcer, gastric adenocarcinoma, and primary gastric lymphoma. As new helicobacter species are now regularly being discovered, Helicobacter covers the entire range of helicobacter research, increasing communication among the fields of gastroenterology; microbiology; vaccine development; laboratory animal science.